Altimmune, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Altimmune, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 94% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-263.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 94% of Healthcare companies in United States.
Cash Cushion Ratio
+56%Cash, after subtracting all debt, equals 56% of its market value (net cash).
Higher than 78% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Altimmune, Inc. made a loss over the last year. Altimmune, Inc. owes $0.10 for every $1 it owns. Altimmune, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAltimmune, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.89The share price is 0.89 times Altimmune, Inc.'s book value per share, lower than 81% of Healthcare companies in United States.
Market cap
$422 MThe total market value of all of Altimmune, Inc.'s shares at today's price (share price × number of shares), larger than 52% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$474 MWhat Altimmune, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.44Net worth divided by the number of shares. The share price of $2.17 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-28.9%Altimmune, Inc. lost 28.9% of its shareholders' money over the last year, higher than 61% of Healthcare companies in United States.
Owes vs Owns
0.10×Altimmune, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Dividend yield
NoneAltimmune, Inc. does not currently pay a dividend.
Revenue growth
+105%Revenue rose 105% in the year to Dec 2025.
Profit growth
LossAltimmune, Inc. made a loss in each of the last two years.
Profit margin
-214861.0%Altimmune, Inc. lost $214861 for every $100 of revenue.
Interest cover
Not coveredAltimmune, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAltimmune, Inc. held $238 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Altimmune, Inc.: $422 M ÷ $474 M (30 Jun 2026) = 0.9.
What is Altimmune, Inc.'s return on equity?
Altimmune, Inc. lost 28.9% of its shareholders' money over the last year, higher than 61% of Healthcare companies in United States.
How much does Altimmune, Inc. owe compared with what it owns?
Altimmune, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Does Altimmune, Inc. pay a dividend?
No. Altimmune, Inc. does not currently pay a dividend.
Is Altimmune, Inc.'s revenue growing?
Revenue rose 105% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.